Affordable Access

deepdyve-link
Publisher Website

Polo-like kinase and survivin are esophageal tumor-specific promoters

Authors
  • Sato, Fumiaki
  • Abraham, John M.
  • Yin, Jing
  • Kan, Takatsugu
  • Ito, Tetsuo
  • Mori, Yuriko
  • Hamilton, James P.
  • Jin, Zhe
  • Cheng, Yulan
  • Paun, Bogdan
  • Berki, Agnes T.
  • Wang, Suna
  • Shimada, Yutaka
  • Meltzer, Stephen J.
Type
Published Article
Journal
Biochemical and Biophysical Research Communications
Publication Date
Jan 01, 2006
Volume
342
Issue
2
Pages
465–471
Identifiers
DOI: 10.1016/j.bbrc.2006.01.177
Source
Elsevier
Keywords
License
Unknown

Abstract

For developing successful cancer gene therapy strategies, tumor-specific gene delivery is essential. In this study, we used esophageal cancer (EC) cells to identify and evaluate esophageal tumor-specific gene promoters. Four genes (polo-like kinase-1/PLK, survivin/BIRC5, karyopherin α 2/KPNA2, and pituitary tumor transforming gene protein 1/PTTG1) were identified by a microarray analysis as highly expressed in EC cell lines vs. five normal organ tissues (liver, lung, kidney, brain, and heart). By quantitative RT-PCR, the average mRNA expression levels of these four genes in 20 primary ECs were 2.7-fold (PLK), 6.1-fold (survivin), 2.6-fold (KPNA2), and 2.4-fold (PTTG1) higher than that of each gene in 24 different normal organs. By dual luciferase assay, the promoter activity of PLK and survivin in EC cell lines was 18.9-fold and 28.5-fold higher, respectively, than in normal lung and renal cells. The promoters of PLK and survivin could be useful tools for developing EC-specific gene therapy vectors.

Report this publication

Statistics

Seen <100 times